Christine Bellon
Known title: Chief Legal OfficerCIK: 0001963878
Associated companies
Transaction History
| BEAM | ▼ Sell | Open Market | 5,956 | $146K | 4/1/2026 | View on chart |
| BEAM | ▲ Buy | Grant | 20,000 | $0 | 3/31/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,371 | $47K | 1/22/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 2,111 | $71K | 1/15/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 15,959 | $554K | 1/15/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 559 | $20K | 1/15/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,254 | $34K | 12/31/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 373 | $9K | 10/1/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 5,674 | $104K | 4/1/2025 | View on chart |
| BEAM | ▲ Buy | Grant | 20,000 | $0 | 3/31/2025 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 9,492 | $69K | 2/14/2025 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 508 | $4K | 2/14/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 10,000 | $340K | 2/14/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,241 | $31K | 1/2/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 385 | $9K | 10/1/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 3,401 | $109K | 4/1/2024 | View on chart |
| BEAM | ▲ Buy | Grant | 27,500 | $0 | 3/31/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,907 | $50K | 1/3/2024 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 4,182 | $30K | 11/20/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 5,818 | $42K | 11/20/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 5,000 | $150K | 11/20/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 5,000 | $155K | 11/20/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 388 | $9K | 10/2/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,161 | $34K | 4/4/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 931 | $28K | 4/3/2023 | View on chart |
| BEAM | ▲ Buy | Grant | 17,500 | $0 | 3/31/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 6,272 | $45K | 3/30/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 2,669 | $19K | 3/30/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress
Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.